Lincolnshire Prescribing and Clinical Effectiveness Forum (PACEF) was founded in 2007. It is the current strategic advisory network to NHS Lincolnshire ICB. PACEF has the responsibility for ensuring the cost-effective use of medicines and other healthcare interventions and their functional integration into healthcare delivery across Lincolnshire.

Representation on the group is comprised of leading professionals from the Lincolnshire Integrated Care Board, primary care, the local Acute Trusts (United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust), Lincolnshire Community Health Services, Local Medical Council and Local Pharmaceutical Council. 

PACEF Bulletins

Title
PACE Bulletin Vol 16 No 4 July 2022 ONS

Description

N/A

PACE Bulletin Vol 16 No 3 July 2022 Asthma

Description

N/A

PACE Bulletin Vol 16 No 2 May 2022

Description

Sativex® Oromucosal Spray approved as RED for treatment of moderate to severe spasticity associated with Multiple Sclerosis.

Buprenorphine Long-acting injection Buvidal® –approved as RED for use only by “We are with you” service.

HRT products – temporary removal of formulary restrictions to manage current supply disruption.

Liothyronine Sodium Capsules (ROMA Pharmaceuticals) approved as AMBER 2.

Atorvastatin 4mg/ml liquid (Rosemount Pharmaceuticals) approved as GREEN to be used when standard tablets or chewable tablets are not appropriate.

Mexiletine Hydrochloride hard capsules 50mg,100mg,200mg (Clinigen Healthcare Ltd) approved as AMBER 2 for use for their licensed indication for the treatment of life-threatening ventricular arrhythmias.

Camouflagers (Covermark®, Dermacolor®, Keromask® & Veil®) approved as AMBER 2

NICE TA 773 Empagliflozin for heart failure – Empagliflozin approved as AMBER 2 for this indication.

NICE TA 775 Dapagliflozin for CKD – Dapagliflozin approved as AMBER 2 for this indication.

PACE Bulletin Vol 16 No 1 Mar 2022

Description

Solaraze® (Diclofenac)3%Gel changed from amber 2 to GREEN for the treatment of actinic keratosis.

Solacutan® (Diclofenac )3% gel approved as GREEN for the treatment of actinic keratosis.

Efudix® (Fluorouracil )5% cream changed from amber 2 to GREEN on formulary for the treatment of non-malignant skin conditions.

Tirbanibulin (Klisyri®) 10mg/g ointment approved as AMBER 2 for the treatment of actinic keratosis.

Lidocaine plasters 5% approved as AMBER 2 for the management of localised neuropathic pain in patients reviewed by the chronic pain service.

Artificial Salvia review of formulary advice all products classed as GREEN

Semaglutide tablets (Rybelsus®) changed from Amber 2 to green when the use of an oral formulation is indicated.

Sodium cromoglicate 100mg capsules (Nalcrom®) approved as AMBER 2 for unlicensed use for treatment of mast cell disorders

Gonadorelin analogues therapy requested for patients who are under of gender dysphoria services.